Group Introduction

Yantai Dongcheng Pharmaceutical Group Co., Ltd. was established in 1998 and listed on the Shenzhen Stock Exchange in May 2012 (stock code 002675). After more than 20 years of development, Dongcheng Pharmaceutical has become a large pharmaceutical enterprise group that covers four major fields: raw materials, formulations, nuclear medicine, and big health, integrating drug research and development, production, and sales.

As a leading enterprise in the heparin industry, the company has a vertically integrated heparin full industry chain, and its heparin API export and chondroitin sulfate production are leading in the industry.

The company has a rich pipeline of formulation products, with production lines for various dosage forms such as powder injections, tablets, capsules, granules, and drop pills. The products cover multiple therapeutic fields such as anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti infection. The company is based on the advantages of heparin raw materials and extends to downstream formulations. Currently, it has reserved multiple varieties of low molecular weight heparin formulations, laying the foundation for continuously building a well-known brand in the field of anticoagulation.

The company is one of the leading nuclear medical enterprises in China and has established a leading domestic network for the production and distribution of radioactive drugs; The products on sale have achieved full coverage of "screening diagnosis treatment"; Multiple innovative varieties under research are in the preclinical and clinical trial stages. The company has initially formed five major platforms: nuclide supply platform, drug incubation platform, transformation service platform, production and distribution platform, and diagnosis and treatment marketing platform. It has basically completed the layout of the entire nuclear medical industry chain from raw material supply, research and development, clinical transformation, production, and sales, and has built a complete Dongcheng Pharmaceutical nuclear medical ecosystem.

The company has been honored with titles such as National Enterprise Technology Center, Ministry of Industry and Information Technology's Specialized and Innovative "Little Giant" Enterprise, Shandong Province Manufacturing Industry Single Champion Enterprise, China's Top 500 New Economy Enterprises, China's Top 100 Chemical and Pharmaceutical Enterprises, Shandong's Top 100 Private Enterprise Innovations, and Shandong's Top 10 Private Enterprises Leading the Modern Marine Industry. The company is a national high-tech enterprise and currently has innovation platforms such as the Provincial Enterprise Technology Center, Provincial Engineering Technology Research Center, Provincial Engineering Research Center, and Provincial Engineering Technology Collaborative Innovation Center.

Guided by the mission of "Based in the East, Watching for Health", Dongcheng Pharmaceutical will deepen resource integration, optimize industrial structure, continuously enhance its innovation capabilities and core competitiveness, and move towards becoming a continuously outstanding pharmaceutical enterprise.